| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
89,554,000 |
| Market
Cap: |
1.86(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.02 - $46.03 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,902 |
53,695 |
61,187 |
62,275 |
| Total Sell Value |
$95,737 |
$1,589,489 |
$1,913,663 |
$1,961,404 |
| Total People Sold |
2 |
8 |
8 |
8 |
| Total Sell Transactions |
2 |
11 |
15 |
16 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dube Michael P |
Principal Accounting Officer |
• – – |
2024-04-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
31,223 |
|
-20% |
|
| Clark Eliana |
EVP, Chief Technical Officer |
• – – |
2024-03-04 |
4 |
S |
$32.99 |
$19,959 |
D/D |
(605) |
71,470 |
|
38% |
|
| Basta James |
EVP, General Counsel |
• – – |
2024-03-04 |
4 |
S |
$32.99 |
$75,778 |
D/D |
(2,297) |
81,571 |
|
38% |
|
| Lebwohl David |
EVP, Chief Medical Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
38,701 |
93,073 |
|
- |
|
| Clark Eliana |
EVP, Chief Technical Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
31,230 |
72,075 |
|
- |
|
| Basta James |
EVP, General Counsel |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,394 |
83,868 |
|
- |
|
| Hicks Derek |
EVP, Chief Business Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
29,393 |
66,380 |
|
- |
|
| Leonard John M. |
President and CEO |
• • – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
113,586 |
960,072 |
|
- |
|
| Goddard Glenn |
EVP, Chief Financial Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
28,628 |
69,213 |
|
- |
|
| Sepp-Lorenzino Laura |
EVP, Chief Scientific Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
37,966 |
81,893 |
|
- |
|
| Sepp-Lorenzino Laura |
EVP, Chief Scientific Officer |
• – – |
2024-01-08 |
4 |
AS |
$28.66 |
$65,682 |
D/D |
(2,275) |
43,927 |
|
-31% |
|
| Basta James |
EVP, General Counsel |
• – – |
2024-01-03 |
4 |
S |
$29.46 |
$112,095 |
D/D |
(3,805) |
51,474 |
|
32% |
|
| Leonard John M. |
President and CEO |
• • – |
2024-01-03 |
4 |
S |
$29.46 |
$566,310 |
D/D |
(19,223) |
846,486 |
|
32% |
|
| Clark Eliana |
EVP, Chief Technical Officer |
• – – |
2024-01-03 |
4 |
S |
$29.46 |
$135,954 |
D/D |
(4,608) |
40,845 |
|
32% |
|
| Sepp-Lorenzino Laura |
EVP, Chief Scientific Officer |
• – – |
2024-01-03 |
4 |
S |
$29.46 |
$162,973 |
D/D |
(5,532) |
46,202 |
|
32% |
|
| Hicks Derek |
EVP, Chief Business Officer |
• – – |
2024-01-03 |
4 |
S |
$29.46 |
$114,216 |
D/D |
(3,877) |
36,987 |
|
32% |
|
| Lebwohl David |
EVP, Chief Medical Officer |
• – – |
2024-01-03 |
4 |
S |
$29.46 |
$172,135 |
D/D |
(5,843) |
54,372 |
|
32% |
|
| Goddard Glenn |
EVP, Chief Financial Officer |
• – – |
2024-01-03 |
4 |
S |
$29.46 |
$158,053 |
D/D |
(5,365) |
40,585 |
|
32% |
|
| Goddard Glenn |
EVP, Chief Financial Officer |
• – – |
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,062 |
45,950 |
|
- |
|
| Sepp-Lorenzino Laura |
EVP, Chief Scientific Officer |
• – – |
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
51,734 |
|
- |
|
| Lebwohl David |
EVP, Chief Medical Officer |
• – – |
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,187 |
60,215 |
|
- |
|
| Leonard John M. |
President and CEO |
• • – |
2024-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,848 |
865,709 |
|
- |
|
| Bhanji Muna |
Director |
– • – |
2023-10-31 |
4 |
AS |
$23.90 |
$6,334 |
D/D |
(265) |
11,996 |
|
11% |
|
| Bhanji Muna |
Director |
– • – |
2023-07-31 |
4 |
AS |
$42.33 |
$11,217 |
D/D |
(265) |
12,261 |
|
-29% |
|
| Bhanji Muna |
Director |
– • – |
2023-07-06 |
4 |
AS |
$39.30 |
$73,373 |
D/D |
(1,867) |
12,526 |
|
-38% |
|
245 Records found
|
|
Page 1 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.74 (3.7%) 
